237 related articles for article (PubMed ID: 21431993)
1. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.
Rhee CW; Lee J; Oh S; Choi NK; Park BJ
Osteoporos Int; 2012 Jan; 23(1):247-54. PubMed ID: 21431993
[TBL] [Abstract][Full Text] [Related]
2. Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.
Herrera L; Leal I; Lapi F; Schuemie M; Arcoraci V; Cipriani F; Sessa E; Vaccheri A; Piccinni C; Staniscia T; Vestri A; Di Bari M; Corrao G; Zambon A; Gregori D; Carle F; Sturkenboom M; Mazzaglia G; Trifiro G
Osteoporos Int; 2015 May; 26(5):1499-506. PubMed ID: 25752621
[TBL] [Abstract][Full Text] [Related]
3. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
Huang WF; Tsai YW; Wen YW; Hsiao FY; Kuo KN; Tsai CR
Menopause; 2010; 17(1):57-63. PubMed ID: 19680161
[TBL] [Abstract][Full Text] [Related]
4. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.
Loke YK; Jeevanantham V; Singh S
Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379
[TBL] [Abstract][Full Text] [Related]
6. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
Calcif Tissue Int; 2010 May; 86(5):335-42. PubMed ID: 20309678
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis.
Bhuriya R; Singh M; Molnar J; Arora R; Khosla S
Int J Cardiol; 2010 Jul; 142(3):213-7. PubMed ID: 20051297
[TBL] [Abstract][Full Text] [Related]
8. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer.
Wilkinson GS; Baillargeon J; Kuo YF; Freeman JL; Goodwin JS
J Clin Oncol; 2010 Nov; 28(33):4898-905. PubMed ID: 20940190
[TBL] [Abstract][Full Text] [Related]
9. Atrial fibrillation in fracture patients treated with oral bisphosphonates.
Abrahamsen B; Eiken P; Brixen K
J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D and bisphosphonates therapies for osteoporosis are associated with different risks of atrial fibrillation in women: A nationwide population-based analysis.
Yang HY; Huang JH; Chiu HW; Lin YK; Hsu CY; Chen YJ
Medicine (Baltimore); 2018 Oct; 97(43):e12947. PubMed ID: 30412111
[TBL] [Abstract][Full Text] [Related]
11. Incidence and Risk of Venous Thromboembolism in Bisphosphonates and Selective Estrogen Receptor Modulators Treatment in Korea.
Park SY; Kim SH; Kim TY; Lee YK; Ha YC; Jang S; Ahn SH; Kim HY
J Korean Med Sci; 2021 Jul; 36(27):e186. PubMed ID: 34254473
[TBL] [Abstract][Full Text] [Related]
12. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
Ringe JD
MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655
[No Abstract] [Full Text] [Related]
13. Bisphosphonates and risk of cardiovascular events: a meta-analysis.
Kim DH; Rogers JR; Fulchino LA; Kim CA; Solomon DH; Kim SC
PLoS One; 2015; 10(4):e0122646. PubMed ID: 25884398
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates and the risk of atrial fibrillation.
Sewerynek E; Stuss M
Endokrynol Pol; 2011; 62(1):93-6. PubMed ID: 21365587
[TBL] [Abstract][Full Text] [Related]
15. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
16. Relation of bisphosphonate therapies and risk of developing atrial fibrillation.
Bunch TJ; Anderson JL; May HT; Muhlestein JB; Horne BD; Crandall BG; Weiss JP; Lappé DL; Osborn JS; Day JD
Am J Cardiol; 2009 Mar; 103(6):824-8. PubMed ID: 19268739
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates and atrial fibrillation: clinical trial data suggest possible link.
Prescrire Int; 2011 Apr; 20(115):96-7. PubMed ID: 21648212
[TBL] [Abstract][Full Text] [Related]
18. Relationship of Bisphosphonate Therapy and Atrial Fibrillation/Flutter: Outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study.
Thadani SR; Ristow B; Blackwell T; Mehra R; Stone KL; Marcus GM; Varosy PD; Cummings SR; Cawthon PM;
Chest; 2016 May; 149(5):1173-80. PubMed ID: 26836889
[TBL] [Abstract][Full Text] [Related]
19. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
John Camm A
Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate use in osteoporosis: cardiovascular effects.
Gallagher JC; Sai AJ
Menopause; 2010; 17(1):5-7. PubMed ID: 19934778
[No Abstract] [Full Text] [Related]
[Next] [New Search]
